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AntagonistsAbstract A series of 2-[4-(aryl substituted) piperazin-1-yl]-N-benzylacetamides were synthesized
and the target compounds (3a–j) were evaluated for atypical antipsychotic activity by studying apo-
morphine induced climbing behavior, 5-HTP induced head twitches behavior and catalepsy in mice.
The physicochemical similarity of the target compounds with respect to standard drugs clozapine,
ketanserin and risperidone was assessed by calculating from a set of physicochemical properties
using software programs. The test compounds (3a–j) demonstrated good similarity values with
respect to the standard drugs. Among them, compound 3b has emerged as an important lead com-
pound showing potential atypical antipsychotic-like proﬁle.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Dopaminergic and serotonergic neurotransmission modulates
the activity of the CNS and its deregulation is associated with
the onset of schizophrenia (Baldessarini and Tarazi, 1996).
Schizophrenia is a complex psychological disorder affecting
about 1% of the population worldwide (Reynolds, 1992). The
use of classical neuroleptics such as chlorpromazine and halo-
peridol are associated with severe mechanism related side effects
including extrapyramidal symptoms (EPS) (Altar et al., 2003;
Stahl, 2000). The adverse effects presented by typical antipsy-
chotic drugs along with their ineffectiveness in the treatment
of negative symptoms of schizophrenia have led, through the
years, to the arduous search for new molecules (Gonzalez-
Gomez et al., 2003). Several dopaminergic, serotonergic and
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atypical antipsychotic drugs. To date, however, the mixed 5-
HT2/D2 receptor antagonism strategy is an important approach
for the development of atypical antipsychotic drugs (Carro
et al., 2009; Meltzer et al., 1989). Long chain arylpiperazines
have been (LCAPs) recognized as the largest and most diverse
classes of compounds exerting actions on the central nervous
system in particular serotonin (5-HT) and dopamine afﬁnity
(Obniska et al., 2003; Gonzalez-Gomez et al., 2003; Kumar
et al., 2011a). Their general chemical structure consists of the
arylpiperazine moiety connected by an alkyl chain with the ter-
minal amide or imide fragment (Gonzalez-Gomez et al., 2003;
Perrone et al., 1999; Kumar et al., 2011b). In view of these
observations, we herein report the synthesis, computational
studies of some new amide arylpiperazines and evaluated them
for a possible atypical antipsychotic potential.2. Materials and methods
2.1. General
Melting points of the synthesized compounds were determined
by open capillary method and are uncorrected. The IR spectra
of synthesized compounds were recorded in potassium bro-
mide discs on Perkin Elmer Spectrum RX1. The 1H and 13C
NMR spectra were recorded on a Bruker DRX-300 spectro-
photometer (1H at 300 MHz and 13C at 75 MHz) in CDCl3
containing TMS as an internal standard. Elemental analyses
were performed on Elementar Vario EL III analyzer. The elec-
trospray mass spectra were recorded on a Thermo Finnigan
LCQ Advantage Max ion trap mass spectrometer. All reagents
were of commercial quality and were used without further
puriﬁcation. The reactions progress was monitored by thin-
layer chromatography (TLC) using silica gel G and spots were
visualized in an iodine chamber.
2.2. Synthesis of compounds
2.2.1. Synthesis of 2-chloro-N-benzylacetamide (2)
Benzylamine 1 (4.37 ml, 0.04 mol) in 2N aqueous sodium
hydroxide (150 ml) was treated with chloroacetylchloride
(3.18 ml, 0.04 mol) as a solution in dichloromethane (100 ml)
at 0 C. After1 h, the layers were separated and the aqueous
phases extracted with an additional portion of dichlorometh-
ane. The organic phases were combined, washed with an aque-
ous solution of 1N HCl, saturated NaHCO3, dried (Na2SO4),
and concentrated to afford 2. Yield: 78%; m.p. 94–96 C; IR
(KBr, cm1): 3268, 3017, 2945, 1669, 1220, 1066, 769, 689.
1H NMR (300 MHz; CDCl3 d): 4.11 (s, 2H); 4.49–4.51 (d,
J= 6, 2H); 6.88 (br s, NH); 7.26–7.39 (m, 5H, Ar-H); Anal.
Calcd. for C9H10ClNO: C, 58.86; H, 5.49; N, 7.63; Found:
C, 58.81; H, 5.43; N, 7.58.
2.2.2. General procedure for the synthesis of 3a–j
2-Chloro-N-benzylacetamide 2 (0.91 g, 0.005 mol) was dis-
solved in 100 ml of acetonitrile in a 250 ml round bottomed
ﬂask. Anhydrous K2CO3 (0.69 g, 0.005 mol) and catalytic
amount of potassium iodide and 0.005 mol of appropriate
arylpiperazine were added to the above solution. The above
mixture was allowed to reﬂux with continuous stirring on amagnetic stirrer for 12 h. After completion of reaction the
solvent was removed by vacuum distillation and residue was
dissolved in chloroform and water. The organic layer was
washed with brine and dried over MgSO4, removal of the sol-
vent afforded target compounds 3a–j.
2.2.2.1. 2-[4-(Phenyl) piperazin-1-yl]-N-benzylacetamide
(3a). Yield: 53%; m.p. 97–100 C; IR (KBr, cm1): 3301,
3061, 2827, 1657, 1213, 1017. 1H NMR (300 MHz; CDCl3
d): 2.67–3.12 (m, 4H, piperazine); 3.13–3.36 (m, 4H, pipera-
zine); 4.39 (s, 2H, COCH2); 4.47 (d, J= 6, 2H, CH2); 6.86–
6.91 (m, 5H, Ar-H); 7.25–7.33 (m, 5H, Ar-H); 7.51 (br s, 1H,
NH). 13C NMR (75 MHz, CDCl3 d): 42.6, 49.0, 53.0, 76.5,
115.3, 118.6, 124.0, 127.3, 128.5, 128.7, 137.9, 150.7, 170.1.
MS (EI) m/z: 310 (M+1). Anal. Calcd. for C19H23N3O: C,
73.76; H, 7.49, N, 13.58. Found: C, 73.61; H, 7.34; N, 13.51.
2.2.2.2. 2-[4-(2-Methoxyphenyl) piperazin-1-yl]-N-benzylace-
tamide (3b). Yield: 48%; m.p. 85–88 C; IR (KBr, cm1):
3307, 3057, 2829, 1664, 1219, 1016. 1H NMR (300 MHz;
CDCl3 d): 2.71–3.06 (m, 4H, piperazine); 3.14–3.36 (m, 4H,
piperazine); 3.81 (s, 3H, OCH3); 4.39 (s, 2H, COCH2); 4.49
(d, J= 6, 2H, CH2); 6.84–7.07 (m, 4H, Ar-H); 7.25–7.34 (m,
5H, Ar-H); 7.53 (br s, 1H, NH). MS (EI) m/z: 340 (M+1).
Anal. Calcd. for C20H25N3O2: C, 70.77; H, 7.42; N, 12.38.
Found: C, 70.67; H, 7.31; N, 12.21.
2.2.2.3. 2-[4-(3-Methoxyphenyl) piperazin-1-yl]-N-benzylace-
tamide (3c). Yield: 44%; m.p. 82-85 C; IR (KBr, cm1):
3307, 3035, 2831, 1661, 1219, 1016. 1H NMR (300 MHz;
CDCl3 d): 2.72–3.06 (m, 4H, piperazine); 3.14–3.36 (m, 4H,
piperazine); 3.78 (s, 3H, OCH3); 4.39 (s, 2H, COCH2); 4.49
(d, J= 6, 2H, CH2); 6.84–7.04 (m, 4H, Ar-H); 7.25–7.32 (m,
5H, Ar-H); 7.53 (br s, 1H, NH). MS (EI) m/z: 340 (M+1).
Anal. Calcd. for C20H25N3O2: C, 70.77; H, 7.42; N, 12.38.
Found: C, 70.63; H, 7.34; N, 12.30.
2.2.2.4. 2-[4-(4-Methoxyphenyl) piperazin-1-yl]-N-benzylace-
tamide (3d). Yield: 37%; m.p. 70–75 C; IR (KBr, cm1):
3301, 3061, 2827, 1661, 1221, 1028. 1H NMR (300 MHz;
CDCl3 d): 2.72–2.92 (m, 4H, piperazine); 3.14–3.36 (m, 4H,
piperazine); 3.76 (s, 3H, OCH3); 4.39 (s, 2H, COCH2); 4.49
(d, J= 6, 2H, CH2); 6.87–7.04 (m, 4H, Ar-H); 7.25 -7.34 (m,
5H, Ar-H); 7.53 (br s, 1H, NH). MS (EI) m/z: 340 (M+1).
Anal. Calcd. for C20H25N3O2: C, 70.77; H, 7.42; N, 12.38.
Found: C, 70.60; H, 7.28; N, 12.25.
2.2.2.5. 2-[4-(3-Methylphenyl) piperazin-1-yl]-N-benzylaceta-
mide (3e). Yield: 51%; m.p. 126–128 C; IR (KBr, cm1):
3309, 3057, 2831, 1659, 1213, 1032. 1H NMR (300 MHz;
CDCl3 d): 2.26 (s, 3H, CH3); 2.73–3.14 (m, 4H, piperazine);
3.19–3.35 (m, 4H, piperazine); 4.41 (s, 2H, COCH2); 4.48 (d,
J= 6, 2H, CH2); 6.80–7.07 (m, 4H, Ar-H); 7.25 -7.34 (m,
5H, Ar-H); 7.48 (br s, 1H, NH). MS (EI) m/z: 324 (M+1).
Anal. Calcd. for C20H25N3O: C, 74.27; H, 7.79; N, 12.99.
Found: C, 74.18; H, 7.67; N, 12.91.
2.2.2.6. 2-[4-(4-Methylphenyl) piperazin-1-yl]-N-benzylaceta-
mide (3f). Yield: 55%; m.p. 89–91 C; IR (KBr, cm1): 3307,
3051, 2829, 1661, 1213, 1032. 1H NMR (300 MHz; CDCl3 d):
2.26 (s, 3H, CH3); 2.73–3.06 (m, 4H, piperazine); 3.10–3.35 (m,
4H, piperazine); 4.41 (s, 2H, COCH2); 4.48 (d, J= 6, 2H,
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Figure 1 The effect of synthesized compounds (3a–j) on the
apomorphine induced climbing behavior. Each column represents
the mean ± SEM of total climbing score for group of six mice
assessed at 5-min intervals for 20 min, starting 10 min after
apomorphine treatment. All values are statistically signiﬁcant with
respect to control at p< 0.05.
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Figure 2 The effect of synthesized compounds (3a–j) on the 5-
HTP induced head twitches behavior. Each column represents the
mean ± SEM of total head twitches score for group of six mice
assessed at 10-min intervals for 30 min, starting 20 after the 5-HTP
treatment. All values are statistically signiﬁcant with respect to
control at p< 0.05.
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Figure 3 Induction of catalepsy of synthesized compounds
(3a–j). Results are expressed as the mean ± SEM. (n= 6). All
values are statistically signiﬁcant with respect to control at
p< 0.05.
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(br s, 1H, NH). MS (EI) m/z: 324 (M+1). Anal. Calcd. for
C20H25N3O: C, 74.27; H, 7.79; N, 12.99. Found: C, 74.21;
H, 7.70; N, 12.93.
2.2.2.7. 2-[4-(2-Chlorophenyl) piperazin-1-yl]-N-benzylaceta-
mide (3g). Yield: 56%; m.p. 153–155 C; IR (KBr, cm1):3311, 3057, 2831, 1664, 1210, 1015. 1H NMR (300 MHz;
CDCl3 d): 2.67–3.11 (m, 4H, piperazine); 3.21–3.35 (m, 4H,
piperazine); 4.43 (s, 2H, COCH2); 4.50 (d, J= 6, 2H, CH2);
6.82–7.15 (m, 4H, Ar-H); 7.25–7.34 (m, 5H, Ar-H); 7.51 (br
s, 1H, NH). MS (EI) m/z: 344 (M+1). Anal. Calcd. for
C19H22ClN3O: C, 66.37; H, 6.45; N, 12.22. Found: C, 66.30;
H, 6.38; N, 12.16.
2.2.2.8. 2-[4-(3-Chlorophenyl) piperazin-1-yl]-N-benzylaceta-
mide (3h). Yield: 48%; m.p. 77–80 C; IR (KBr, cm1): 3313,
3059, 2829, 1667, 1213, 1012. 1H NMR (300 MHz; CDCl3 d):
2.67–3.11 (m, 4H, piperazine); 3.21–3.35 (m, 4H, piperazine);
4.43 (s, 2H, COCH2); 4.50 (d, J= 6, 2H, CH2); 6.84–7.03
(m, 4H, Ar-H); 7.15–7.32 (m, 5H, Ar-H); 7.51 (br s, 1H,
NH). MS (EI) m/z: 344 (M+1). Anal. Calcd. for
C19H22ClN3O: C, 66.37; H, 6.45; N, 12.22. Found: C, 66.28;
H, 6.35; N, 12.18.
2.2.2.9. 2-[4-(4-Nitrophenyl) piperazin-1-yl]-N-benzylaceta-
mide (3i). Yield: 62%; m.p. 156–158 C; IR (KBr, cm1):
3301, 3030, 2823, 1661, 1251, 1004. 1H NMR (300 MHz;
CDCl3 d): 2.67–3.10 (m, 4H, piperazine); 3.13–3.35 (m, 4H,
piperazine); 4.41 (s, 2H, COCH2); 4.48 (d, J= 6, 2H, CH2);
6.62–7.07 (m, 4H, Ar-H); 7.25–7.34 (m, 5H, Ar-H); 7.60 (br
s, 1H, NH). MS (EI) m/z: 355 (M+1). Anal. Calcd. for
C19H22N4O3: C, 64.39; H, 6.26; N, 15.81. Found: C, 64.31;
H, 6.20; N, 15.76.
2.2.2.10. 2-[4-(4-Fluorophenyl) piperazin-1-yl]-N- benzylaceta-
mide (3j).Yield: 58%; m.p. 123–125 C; IR (KBr, cm1): 3307,
3041, 2827, 1657, 1213, 1013. 1H NMR (300 MHz; CDCl3 d):
2.72–3.10 (m, 4H, piperazine); 3.12–3.36 (m, 4H, piperazine);
4.41 (s, 2H, COCH2); 4.48 (d, J= 6, 2H, CH2); 6.84–7.02 (m,
4H, Ar-H); 7.15–7.32 (m, 5H, Ar-H); 7.48 (br s, 1H, NH).
MS (EI) m/z: 328 (M+1). Anal. Calcd. for C19H22FN3O: C,
69.70; H, 6.77; N, 12.83. Found: C, 69.68; H, 6.45; N, 12.66.
2.3. Computational studies
2.3.1. Computation of physiochemical properties
A set of molecular parameters were computed for the target
compounds as well as three standard drugs clozapine, ketan-
serin and risperidone using Chem 3D Ultra version, 11.0,
and Chem Silico online free software. The important molecu-
lar parameters for antipsychotics are blood-brain barrier
(BBB), logP and topological polar surface area. The literature
review suggests that TPSA is a measure of a molecule’s hydro-
gen bonding capacity and its value should not a exceed certain
limit if the compound is intended to be CNS active. Two dif-
fering limits have been proposed: van de Waterbeemed et al.
(1998) suggested a limit of 90 A2, where, Kelder et al. (1999)
suggested 60–70 A2.
2.3.2. Similarity calculations
The physicochemical similarity of the target compounds was
calculated with respect to the standard drugs (Bali et al., 2010).
Firstly, the distance di of a particular target compound j to
drug molecules e.g., clozapine was calculated by the formula:
d2i ¼
Pn
j¼1
ð1 Xi;j=Xi;stdÞ2=n
Table 1 Substituent of compounds 3a–j.
Compd. no. Compd code. R
1 3a H
2 3b 2-OCH3
3 3c 3-OCH3
4 3d 4-OCH3
5 3e 3-CH3
6 3f 4-CH3
7 3g 2-Cl
8 3h 3-Cl
9 3i 4-NO2
10 3j 4-F
CH2NH2
(1)
ClCOCH2Cl
i
CH2NHCOCH2Cl
(2)
ii NHN
R
CH2NHCOCH2 N N
R
(3a-j)
Scheme 1 Synthesis of the target compounds. Reagents and conditions: (i) NaOH, dichloromethane (ii) acetonitrile, K2CO3, KI.
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‘j’, Xi,std is the value of the same molecular parameter for the
standard drug, e.g., clozapine, ketanserin and risperidone.
Then, the similarity of compound ‘j’ to the standard drug
was calculated as
Similarity ð%Þ ¼ ð1 RÞ  100 where R=pd2 is the
quadratic mean (root mean square), a measure of central
tendency.
2.4. Preliminary pharmacological evaluation for atypical
antipsychotic effect
All the target compounds were subjected to preliminary phar-
macological evaluation to determine their ability to inhibit
apomorphine induced climbing behavior (Chung et al.,
2002), inhibit 5-hydroxy tryptophan (5-HTP) induced head
twitches behavior (Chung et al., 2002) and catalepsy studies
(Kumar et al., 2011a,b; Ferre et al., 1990). Prior permission
of the Animal Ethics Committee was obtained and all experi-
ments were conducted according to the approved protocol
(837/ac/04/CPCSEA). Clozapine and haloperidol group were
employed as standard (positive control). Statistical analysis
of the results in the test group was done by comparison with
the results in the control group employing non-parametric
Kruskal Wallis test or one way ANOVA (Jandel Sigmastat
version 2.0). Level of signiﬁcance was ﬁxed at p< 0.05.
2.4.1. Apomorphine induced mesh climbing behavior
Swiss albino mice (six mice in each group) of either sex
(24–26 g) were habituated by individually placing in a circular
cage made of wire mesh of diameter 13 cm and height 14 cm.
Mice in the test, control and standard groups were injected,
respectively, with test compound, normal saline and clozapine
intraperitoneally and returned to the home cage. After a gap of10 min, apomorphine (2.5 mg/kg) was injected intraperitone-
ally. Mesh climbing behavior was noted at 5 min intervals
for up to 20 min, starting 10 min after the apomorphine
administration using the following scoring system: 0 – no paws
on the cage, 1 – one paw on the cage, 2 – two paws on the cage,
3 – three paws on the cage, 4 – four paws on the cage (Fig. 1).
The score recorded for each animal was based on the position
of the animal at the moment it was ﬁrst observed. A score of 20
is the maximum possible. Recording was done by an observer
who was unaware of the speciﬁc drug treatments.
2.4.2. 5-Hydoxytryptophan (5-HTP) induced head twitches
behavior
Swiss albino mice in the control group (n= 6) was injected
with pargyline (75 mg/kg, i.p.) in order to prevent the rapid
degradation of 5-HTP. Thirty minutes later, the test com-
pound was administered. After a further 30 min, the mice re-
ceived 5-HTP (50 mg/kg, i.p.). The mice were returned to the
test cages and then head twitches were assessed at 10 min inter-
vals for 30 min, starting 20 min after the 5-HTP treatment.
Table 2 Calculation of molecular properties for target compounds and standard drugs.
Comp. code logBBi logP M.W.a MRb SAS (A2)c MSA (A2)d SEV (A3)e TPSAf MTIg WIh
3a 0.32 2.66 309.41 94.66 575.217 307.199 280.758 35.58 11308 1458
3b 0.27 2.53 339.43 101.91 638.833 338.01 301.468 44.81 13673 1802
3c 0.25 2.53 339.43 101.91 650.064 341.557 300.50 44.81 13901 1836
3d 0.25 2.53 339.43 101.91 650.116 340.422 298.864 44.81 14129 1870
3e 0.40 3.15 323.43 100.56 606.47 325.882 297.658 35.58 12691 1635
3f 0.40 3.15 323.43 100.56 635.774 332.971 292.45 35.58 12822 1652
3g 0.35 3.22 343.85 99.26 614.289 322.626 287.173 35.58 12077 1618
3h 0.37 3.22 343.85 99.26 623.463 326.608 287.197 35.58 12157 1635
3i 0.20 1.28 354.40 98.64 649.164 341.967 300.969 87.39 15135 2090
3j 0.32 2.82 327.40 95.06 610.728 317.941 278.769 35.58 12237 1652
CLZj 0.75 3.71 326.82 94.58 508.991 259.124 215.892 30.87 8127 1082
KETk 0.48 2.37 395.43 106.67 589.34 298.729 253.338 69.72 18646 2596
RISl 0.20 2.10 410.48 114.21 690.021 375.09 351.81 57.50 20311 2793
a Molecular weight.
b Molar refractivity.
c Connolly solvent accessible surface area.
d Connolly molecular surface area.
e Connolly solvent excluded volume.
f Topological polar surface area.
g Molecular topological index.
h Wienner index.
i Calcd. online (chemsilico.com).
j Clozapine.
k Ketanserin.
l Risperidone.
S1454 S. Kumar et al.Head twitches were monitored using the following scoring sys-
tem: 0 – absent, 1 – moderate, 2 – marked (Fig. 2). A score of
20 is the maximum possible. An observer made all observa-
tions unaware of the speciﬁc drug treatments.
2.4.3. Catalepsy
Catalepsy was induced in albino mice (n= 6) with haloperidol
(1.0 mg/kg, i.p.) and was assessed at 30 min intervals until
120 min and at the end of 240 min by means of a standard
bar test. Catalepsy was assessed in terms of the time (s) for
which the mouse maintained an imposed position with both
front limbs extended and resting on a 4 cm high wooden bar
(1.0 cm diameter). The endpoint of catalepsy was considered
to occur when both front paws were removed from the bar
or if the animal moved its head in an exploratory manner.
The cataleptic behavior was scored as 1 if the imposed posture
was maintained for at least 20 s and every additional 20 s one
extra point was given for severity of catalepsy (Fig. 3). A cut-
off time of 1100 s was applied during the recording of observa-
tions. The animals were returned to their individual home
cages in between determinations. All observations were made
between 10.00 and 16.00 h in a quiet room at 23–25 C. The
animals in the test group were administered with test drugs in-
stead of haloperidol and the remaining procedure for assess-
ment of catalepsy was same as mentioned above.
3. Results and discussion
3.1. Synthesis of compounds
The target compounds 2-[4-(aryl substituted) piperazin-1-yl]-
N-benzylacetamides (3a–j) were synthesized by benzylamine
(1) in 2N sodium hydroxide treated with chloroacetylchloridein dichloromethane to afford 2-chloro-N-benzylacetamide
(2). The IR spectrum of compound (2) showed characteristic
carbonyl group absorption peak at 1669 cm1 and 1H NMR
spectrum exhibited a broad singlet due to NH group at
6.88 ppm. Compound (2) on treatment with appropriate phe-
nylpiperazine in acetonitrile in the presence of K2CO3 and
KI yielded the target compounds (3a–j). All the target com-
pounds (3a–j) were obtained in good yield (37–62%) and char-
acterized by analytical and spectroscopic methods. Mass
spectra of target compounds showed characteristic M+1 peak.
The reactions are outlined in Scheme 1 and the nature of the
substituent is given in Table 1.3.2. Computational studies
A set of molecular parameters were computed for the target
compounds as well as three standard drugs clozapine, ketan-
serin and risperidone using Chem 3D Ultra version, 11.0,
and Chem Silico online free software are shown in Table 2.
The important molecular parameters for antipsychotics are
blood-brain barrier (BBB), logP and topological polar surface
area (TPSA). Literature review suggested that TPSA is a mea-
sure of a molecule’s hydrogen bonding capacity and its value
should not exceed a certain limit if the compound is intended
to be CNS active. Two differing limits have been proposed:
van de Waterbeemed et al. suggested a limit of 90 A2, where,
Kelder et al. suggested 60–70 A2. The TPSA value for test
compounds (3a–j) were well within these limits (35.58–87.39)
which shows that these compounds have a potential to effec-
tively cross the blood-brain barrier. The logBB values (0.20
to 0.40) and log P values (1.28–3.22) for the test compounds
were noted and suggesting that these have an excellent poten-
tial for CNS activity. The physicochemical similarity of the test
Table 4 Potential for atypical antipsychotic activity in vivo.
Compd.
code
Inhibition of apomorphine induced
climbing behavior (ED50, mg/kg, i.p.)
Inhibition of 5-HTP induced head
twitches behavior (ED50, mg/kg, i.p.)
Induction of catalepsy
(ED50, mg/kg, i.p.)
3a 21.3 11.2 35.0
3b 10.0 7.5 40.0
3c 10.5 8.5 45.0
3d 27.1 10.2 40.0
3e >40 23.4 >50
3f >40 23.2 >50
3g 22.0 10.5 44.2
3h 22.5 13.2 43.2
3i >40 >40 >50
3j 29.2 15.2 38.7
Clozapine 8.7
2.8
–
Haloperidol –
–
nda
a nd: not determined, 1 mg/kg dose was used.
Table 3 Similarity values of target compounds with respect to the standard drugs.
Compd. code Similaritya, b (%) to
Clozapine Ketanserin Risperidone
3a 76.52 69.90 69.14
3b 57.60 78.35 78.82
3c 56.21 78.61 79.38
3d 55.13 79.11 79.79
3e 67.39 73.66 73.24
3f 66.31 73.95 73.66
3g 69.95 73.69 72.71
3h 69.11 73.78 73.03
3i 18.55 83.39 75.81
3j 69.73 73.84 72.18
a (1  R) · 100, where R= quadratic mean (root mean square mean).
b Calcd. from physicochemical properties: molecular weight; molar refractivity; Connolly solvent accessible surface area; Connolly molecular
surface area; Connolly solvent excluded volume; topological polar surface area; molecular topological index; Wiener index.
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drugs and shown in Table 3. Most of the compounds showed
good similarity with respect to standard drugs. Among them,
compounds 3b showed good structural similarity with respect
to clozapine, ketanserine and risperidone, respectively
(57.60%, 78.35% and 78.82%).
3.3. Preliminary pharmacological evaluation for antipsychotic
effect
The results of pharmacological evaluation of the target com-
pounds are depicted graphically in Figs. 1–3 and in Table 4.
All the ligands showed signiﬁcant interactions with the dopa-
mine and serotonin receptors, which were found to be depen-
dent, fundamentally on the substitution of the N4-aryl group
of the piperazine ring. With respect to the dopamine receptor,
compounds bearing a methoxy group at ortho, meta and para
position of aryl moiety of piperazine ring (3b, 3c and 3d) pro-
duced statistically signiﬁcant reduction in apomorphine in-
duced climbing behavior than chloro analogs (3g and 3h). Asigniﬁcant reduction in activity was observed, when nitro
group was present at para position of aryl moiety of piperazine
ring (3i). Other compounds (3a, 3e, 3f and 3j) have lesser efﬁ-
cacy for the dopamine receptor. Regarding the serotonin
receptor, the methoxy analogs (3b, 3c and 3d) showed higher
inhibition of 5-hydroxy tryptophan (5-HTP) induced head
twitches behavior than chloro analogs (3g and 3h). Highest
reduction in activity was observed when methyl or nitro substi-
tuent was present on arylpiperazine ring (3e, 3f and 3i). The
other compounds (3a, and 3j) showed lower activity for the
serotonin receptor. The catalepsy results showed all the new
compounds (3a–j) were less cataleptogenic than haloperidol.
Among them, methoxy analogs 3b exhibited lower propensity
to produce catalepsy.4. Conclusion
A new series of arylpiperazines have been synthesized and their
preliminary pharmacological evaluation has shown potential
atypical antipsychotic effect in behavioral models. However,
S1456 S. Kumar et al.in vivo results are insufﬁcient for prediction of an atypical
antipsychotic proﬁle similar to clozapine. Among the
compounds, 3b has shown potent atypical antipsychotic
activity probably by inhibition of dopamine D2 and serotonin
5-HT2 receptors and low induction of catalepsy. Moreover,
TPSA, logBB, logP values suggested that this compound
has the potential to penetrate the blood-brain barrier and
showed good similarity with respect to standard drugs.
Further studies on this lead including in vitro assays are re-
quired for the reﬁnement of the atypical antipsychotic activity.
Competing interests
The authors declare no conﬂict of interest.Acknowledgements
The authors are grateful to Prof. R.M. Dubey, Managing
Director, IFTM, Moradabad, for providing the research facil-
ities and also thankful to the Head, sophisticated analytical
instrument facility, CDRI, Lucknow, for spectral analysis.
This work is a part of work done for Ph.D. degree of the
Shobhit University by Sushil Kumar.References
Altar, C.A., Martin, A.R., Thurkauf, A., Abraham, D.J., 2003.
Burger’s Medicinal Chemistry and Drug Discovery, sixth ed. John
Wiley & Sons, New Jersey, p. 599.
Baldessarini, R.J., Tarazi, F.I., 1996. Brain dopamine receptors: a
primer on their current status, basic and clinical. Harv. Rev.
Psychiatry 3, 301–325.
Bali, A., Sharma, K., Bhalla, A., Bala, S., Reddy, D., Singh, A.,
Kumar, A., 2010. Synthesis, evaluation and computational studies
on a series of acetophenone based 1-(aryloxypropyl)-4-(chloroaryl)
piperazines as potential atypical antipsychotics. Eur. J. Med.
Chem. 45, 2656–2662.
Carro, L., Ravina, E., Dominguez, E., Brea, J., Loza, M.I., Masaguer,
C.F., 2009. Synthesis and binding afﬁnity of potential atypical
antipsychotics with the tetrahydroquinazolinone motif. Bioorg.
Med. Chem. Lett. 19, 6059–6062.
Chemsilico.com/CS_prBBB/BBBdata.html.Chung, I.W., Moore, N.A., Oh, W.K., Neill, M.F.O., Ahn, J.S., Park,
J.B., Kang, U.G., Kim, Y.S., 2002. Behavioural pharmacology of
polygalasaponins indicates potential antipsychotic efﬁcacy. Phar-
macol. Biochem. Behav. 71, 191–195.
Ferre, S., Guix, T., Prat, G., Jane, F., Casas, M., 1990. Is experimental
catalepsy properly measured? Pharmacol. Biochem. Behav. 35,
753–757.
Gonzalez-Gomez, J.C., Santana, L., Uriarte, E., Brea, J., Villazon, M.,
Loza, M.I., Deuca, M., Rivas, M.E., Montenegro, G.Y., Fontenla,
J.A., 2003. New arylpiperazine derivatives with high afﬁnity for 1A,
D2 and 5-HT2A receptors. Bioorg. Med. Chem. Lett. 113, 175–178.
Kelder, J., Grootenhuis, P.D.J., Bayada, D.M., Delbressine, L.P.C.,
Ploemen, J.P., 1999. Polar molecular surface as a dominating
determinant for oral absorption and brain penetration of drugs.
Pharm. Res. 16, 1514–1519.
Kumar, S., Wahi, A.K., Singh, R., 2011a. Synthesis, computational
studies and preliminary pharmacological evaluation of 2-[4-(aryl
substituted) piperazin-1-yl] N,N-diphenylacetamides as potential
antipsychotics. Eur. J. Med. Chem. 46 (9), 4753–4759.
Kumar, S., Wahi, A.K., Singh, R., 2011b. Synthesis and preliminary
pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-
yl]-N-phenylacetamides: as potential antipsychotics. Trop. J.
Pharm. Res. 10 (3), 265–272.
Meltzer, H.Y., Masubara, S., Lee, J.C., 1989. The ratios of serotonin-2
and dopamine-2 afﬁnities differentiate atypical and typical anti-
psychotic drugs. Psychopharmacol. Bull. 25, 390–392.
Obniska, J., Pawlowski, M., Kolaczkowski, M., Czopek, A., Dus-
zynska, B., Klodzinska, A., Tatarczynska, E., Wojcik, E.C., 2003.
Synthesis and 5-HT1A/5-HT2A receptor activity of new N-[3-(4-
phenylpiperazin-1-yl)-propyl] derivatives of 3-spiro-cyclohexane-
pyrrolidine-2,5-dione and 3-spiro-b-tetralonepyrrolidine-2,5-dione.
Pol. J. Pharmacol. 55, 553–557.
Perrone, R., Berardi, F., Colabufo, N.A., Leopoldo, M., Tortorella,
V.J., 1999. 1-Aryl-4-[(5-methoxy-1, 2, 3, 4-tetrahydronaphthalen-1-
yl) alkyl] piperazines and their analogues: inﬂuence of the stereo-
chemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A
receptor afﬁnity and selectivity versus a1 and D2 receptors. J. Med.
Chem. 42, 490–496.
Reynolds, G.P., 1992. Developments in the drug treatment of
schizophrenia. Trends Pharmacol. Sci. 13 (3), 116–121.
Stahl, S.M., 2000. Essential Psychopharmacology: Neuroscientiﬁc
Basis and Practical Applications, second ed. Cambridge University
Press, New York, pp. 401–458.
Waterbeemed, H., Camenishch, G., Folkers, G., Chretien, J.R.,
Raevsky, O.A., 1998. Estimation of blood-brain barrier crossing
of drugs using molecular size and shape, and H-bonding descrip-
tors. J. Drugs Target 6, 151–165.
